BIODANE PHARMA A/S: Financial statements 2016
CVR: 28310102
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
BIODANE PHARMA A/S (CVR 28310102) has filed annual accounts for 2016. In 2016, the company reported a gross profit of DKK 747,313 and a net result of DKK 32,975 compared with DKK -253,036 the year before. That is an increase of 70.6% compared with the year before. Equity in the 2016 report amounted to DKK 766,517. The solvency ratio was 80.9%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 747,313
- Profit/Loss
- DKK 32,975
- Equity
- DKK 766,517
- Total Assets
- DKK 947,244
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | - | 747 t. | 33 t. | 767 t. | 1 |
| 2015 | - | 438 t. | -253 t. | 734 t. | - |
| 2014 | - | 279 t. | -250 t. | 987 t. | - |
| 2013 | - | 106 t. | -977 t. | -263 t. | - |
| 2012 | - | 384 t. | 8 t. | 714 t. | - |
Official annual report
Find more companies like BIODANE PHARMA A/S
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2016
BIODANE PHARMA A/S has published its annual report for 2015. Gross profit came to DKK 437,995, and the net result was DKK -253,036.
About BIODANE PHARMA A/S
BIODANE PHARMA A/S is a Danish company of the type Aktieselskab based in Gesten, founded in 2004. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named BIODANE PHARMA ApS and BIOFIBER TØRRING ApS. The management consists of Gunner Kreutzer Jakobsen. The board consists of Peter Gæmelke (chair), Flemming Torben Heden Knudsen, Gunner Kreutzer Jakobsen and Rasmus Juhl Rasmussen. The company is owned by BIODAN A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 2,534,166 and a net result of DKK 182,862 compared with DKK 1,651,356 the year before. Equity in the 2025 report amounted to DKK 2,505,002.